Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)

Study Summary

The main goals are after treatment given before surgery, to measure the number of people who have no signs of cancer cells in tumors and lymph nodes removed during surgery; and to learn about whether the cancer gets smaller or goes away by measuring the number of people with a certain number of living cancer cells in the tumor removed during surgery.

Conditions

Lung Neoplasm Malignant

Interventions / Drugs

Pembrolizumab (neoadjuvant)Cisplatin Gemcitabine Pemetrexed Sacituzumab tirumotecan H1 receptor antagonist H2 receptor antagonist Acetaminophen (or equivalent)Dexamethasone (or equivalent)Carboplatin Pembrolizumab (adjuvant)Paclitaxel Steroid mouthwash (dexamethasone or equivalent)

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment60 participants

Primary Completion—

Lead SponsorMerck Sharp & Dohme LLC

Data Retrieved2026-04-11 02:55:36.205372+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.